There are two main types of bipolar disorder: bipolar 1 and bipolar 2. Both bipolar 1 and bipolar 2 both cause intense mood swings and energy fluctuations. However, the biggest difference is that ...

Bipolar disorders are currently divided into 4 entities: bipolar I, bipolar II, cyclothymic disorder, and bipolar disorder not otherwise specified, as described in the fourth edition of the ...

There are two primary types of bipolar disorder: Bipolar I and Bipolar II. A major depressive episode may or may not accompany bipolar I, but does accompany bipolar II. People with bipolar I have ...

People with bipolar disorder may be at a higher risk of developing premenstrual dysphoric disorder (PMDD), but neither condition directly causes the other.

There are three types of bipolar disorder: bipolar 1, bipolar 2 , and cyclothymia. All types cause changes in mood, energy, and activity levels. In bipolar 1, moods range from extreme elevation ...

In the largest genome-wide study of bipolar disorder to date, an international team of psychiatric genetics researchers has ...

Antipsychotic medications can help a person with bipolar disorder stabilize their moods, reduce agitation, and improve overall quality of life. Learn more about the medication types, dosage, side ...

Conversano says he has Bipolar II Disorder and that he has dealt with substance abuse and addiction. He will celebrate five years of sobriety this coming February. “Honestly, getting sober has ...

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

The Phase 2 trial aims to establish biological and clinical proof-of-concept for ABX-002 in bipolar depression and will inform Autobahn’s further clinical development strategy. “Bipolar ...

Bipolar disorder is a brain disorder that can cause mood swings, changes in energy levels, and interfere with a person's ability to function. Often misunderstood and difficult to diagnose, bipolar ...

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...